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Objectives. This study assessed the prognostic impact of right
ventricular involvement (RVI) in streptokinase-treated patients
with inferior acute myocardial infarction (AMI) stratified for
small or large AMI.
Background. Only scant data exist from small studies about the
impact of reperfusion therapy on survival in patients with RVI
during inferior AMI.
Methods. Right ventricular involvement was assessed by ST-
segment elevation >20.1 mV in lead V4R and infarct size by the
extent of ST-segment deviation on the baseline electrocardiogram:
small AMI 5 sum ST-segment elevation <20.8 mV and no precor-
dial ST-segment depression (small ST); large AMI 5 presence of
precordial ST-segment depression or sum ST-segment elevation
>0.8 mV (large ST) in 522 inferior AMI patients of the Hirudin
for Improvement of Thrombolysis (HIT-4) Trial. In 187 patients,
90-min coronary angiography was performed.
Results. Right ventricular involvement was present in 169
patients (32%). Higher 30-day cardiac mortality rates with RVI
(5.9% vs. 2.5%) were related to larger infarct size rather than to
RVI. For large ST, a proximal right coronary artery lesion was
observed in 52% with and in 23% without RVI. Patency rates at
90 min were similar (54% vs. 52%). In the 28% of patients who had
small ST, cardiac mortality was less than 1% irrespective of the
presence of RVI. Coronary artery lesions were mostly located
distally. Patency rates were 27% with and 80% without RVI.
Conclusions. ST-segment elevation of >20.1 mV in V4R in
inferior AMI patients is associated with larger infarct size and
higher 30-day mortality rates. Right ventricular involvement is
not an independent predictor of survival. In patients with small
ST, cardiac mortality is low, even if ST V4R is >20.1 mV.
(J Am Coll Cardiol 1998;32:876–81)
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The risk-to-benefit ratio of thrombolytic therapy in patients
with inferior acute myocardial infarction (AMI) continues to
be controversial (1–5). It has been suggested that patients with
inferior AMI only benefit from thrombolytic therapy when
presenting with larger ST-segment deviations (5) or when right
ventricular involvement (RVI) is present (3). Right ventricular
involvement has been shown to occur in at least one third of
patients suffering an inferior AMI (6). Without thrombolytic
therapy in these patients, a significantly increased risk of major
complications and in-hospital death has been reported (6–9).
Data on the benefits of thrombolytic therapy or primary
coronary angioplasty are limited and partly controversial
(3,9,10–15). All studies are limited by very small sample sizes.
Right ventricular involvement during inferior AMI can be
diagnosed with predictive accuracy well above 80% by the
presence of ST-segment elevation of $0.1 mV in the right
chest lead V4R (8,16,17). During the first 12 h of inferior AMI,
combined electrocardiographic criteria were not better diag-
nostically or prognostically than ST-segment elevation in V4R
alone (18). In the Hirudin for Improvement of Thrombolysis
(HIT)-4 Study (19), along with the baseline 12-lead electrocar-
diogram (ECG) the right chest lead V4R was recorded to
compare prospectively the outcome in inferior AMI patients
with or without RVI. In addition, from the HIT-4 angiographic
substudy (20), location and patency status of the infarct-related
coronary artery lesion 90 min after start of thrombolytic
therapy could be compared in patients with or without RVI.
Methods
The HIT-4 Study was a multicenter, double-blind random-
ized trial which compared r-hirudin and heparin as adjuncts to
streptokinase in patients within 6 h of onset of AMI (19). The
primary objective was to demonstrate higher 90-min infarct-
related coronary artery patency rates with r-hirudin in a subset
of 400 patients in whom early angiography had been per-
formed (20). Patients above 18 years were eligible for random-
ization if they had no contraindication to thrombolytic therapy
and had ST-segment elevation $0.1 mV in at least two limb
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leads or $0.2 mV in two contiguous chest leads or presence of
bundle branch block.
Study patients. Of all 1,208 patients recruited for the
HIT-4 study, 522 patients with inferior AMI were considered
for analysis. They did show the required amount of ST-
segment elevation, had no bundle branch block and had
received streptokinase.
Electrocardiographic analysis. A 12-lead ECG and the
right chest lead V4R were recorded before randomization.
ST-segment elevation was measured with lens-intensified cal-
iper to the nearest of 0.025 mV 20 ms after the end of the QRS
complex from leads II, III, aVF, V5 and V6. Reference baseline
for the ST amplitude measurement is the PR segment imme-
diately preceding QRS onset. Reciprocal ST-segment devia-
tions in leads with $0.1 mV depression were measured from
leads V1 to V4. The intensity of the initial epicardial injury was
quantified by the sum of ST-segment elevation from the
aforementioned leads by excluding V4R. The number of leads
with ST-segment elevation $0.1 mV were also counted. Eval-
uation was performed centrally independent of and blinded to
the other study data or results.
According to a study about the prognostic impact of initial
ST-segment changes for thrombolytic treatment in first inferior
AMI (5), subgroup analyses were performed with either small
(small ST) or large (large ST) initial ST-segment deviations.
Small ST was defined as ¥ ST-segment elevation #0.8 mV and
no precordial ST-segment depression, that is, $0.1 mV ST-
segment depression in at most one of leads V1 to V4. Large ST
was defined as presence of ST-segment depression of $0.1 mV
in at least two of leads V1 to V4 or ¥ ST-segment elevation
.0.8 mV.
Enzyme analysis. Peak creatine kinase (CK) isoenzyme
serum activity was measured in the participating hospitals and
is expressed as fraction of the upper normal limit of the
different method used. Enzyme data are available from 515
patients (99%).
Quantitative angiographic analysis. In the angiographic
substudy, coronary angiography was performed 90 min after
start of streptokinase infusion. Cinefilms were sent to a core
lab and evaluated independent of and blinded to the other
study data or results. In 187 patients with inferior AMI, the
infarct-related artery could be identified and the Thrombolysis
In Myocardial Infarction flow grade assessed. Vessel disease is
defined as .50% stenosis in a major epicardial artery. Proxi-
mal coronary artery lesion is defined as proximal to the origin
of any right ventricular branches.
Statistical analysis. For univariate analyses only nonpara-
metric methods were applied. For comparisons of two depen-
dent/independent samples, Wilcoxon signed rank test/Mann–
Whitney U tests or Fisher’s exact test were applied. For
comparisons of three or more independent samples we used
Kruskal–Wallis tests.
The multivariate analysis consisted of a stepwise logistic
regression for outcome at 30 days. In addition to presence of
ST-segment elevation $0.1 mV in lead V4R, nine variables
were offered as covariates: 1) age (taken as a continuous
variable, unit 10 years); 2) gender; 3) previous AMI; 4)
diabetes mellitus; 5) history of angina pectoris; 6) ex-smoker or
nonsmoker; 7) Killip class .1; 8) large ST; 9) treatment with
r-hirudin. In a second analysis peak CK .12 times fraction of
the upper normal limit was added as potential covariate. To
eliminate bias caused by missing data, two patients, who died
from cardiac failure before the maximum CK value could be
obtained, were assigned to peak CK .12.
Logistic regression was performed using the procedure
“LOGISTIC REGRESSION” of SPSS for Windows, version
6.1.3, choosing the forward-stepping selection method with
ML estimates and the defaults criteria offered by SPSS. The
odds ratios, confidence intervals and p values of the final
model (i.e., adjusted for all other significant covariates) are
reported.
Results
Clinical characteristics of the 522 study patients are dis-
played in Table 1. ST-segment elevation of $0.1 mV in lead
V4R at baseline was present in 169 patients (32%). Compared
with patients without ST-segment elevation in the right chest
lead, no differences were observed between groups in the
clinical and demographic characteristics except for a higher
proportion of females with RVI. Intensity of ischemia as
measured by the sum of ST-segment elevation at baseline was
more severe in patients with RVI both in all patients and in
those with large ST at baseline. Total ST-segment deviation
was only slightly larger with RVI probably because RVI
attenuates precordial ST-segment depression in inferior AMI.
The extent of ischemia as assessed by the number of leads with
ST-segment elevation $0.1 mV (V4R not included) was not
different between groups. The peak level of CK was higher
with RVI both in all patients and in the subgroup with large
ST; this was statistically significant only in the total group of all
patients.
Clinical course. More patients with RVI suffered a com-
plicated in-hospital course (Table 2). However, a significant
difference was only observed for the incidence of malignant
tachyarrhythmia. A higher reinfarction rate reached marginal
significance. High degree atrioventricular block and severe
bradycardia are not included in Table 2 because these variables
were not prospectively collected in the HIT-4 study.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CK 5 creatine kinase
ECG 5 electrocardiogram
HIT 5 Hirudin for Improvement of Thrombolysis
large ST 5 Presence of precordial ST-segment depression or ST-
segment elevation .0.8 mV
small ST 5 ST-segment elevation #0.8 mV and no precordial
ST-segment depression
RVI 5 right ventricular involvement
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Mortality. Total 30-day mortality was not significantly dif-
ferent between groups, but cardiac mortality was significantly
higher with RVI (Table 3). A higher cardiac mortality was
restricted to patients with large ST. In 147 patients with small
ST, only 1 died from cardiac cause while 4 suffered a noncar-
diac death (1 stroke, 1 lethal bleeding complication, 1 fulmi-
nant pulmonary embolism after angiography, and 1 worsening
leukemia).
Independent determinants of 30-day cardiac mortality were
assessed by multiple logistic regression analysis (Table 4). The
first analysis, in addition to other prognostic factors available at
the time of admission, includes large ST-segment elevation on
the baseline ECG. In a second analysis (B in Table 4) peak CK
.12 times of the upper normal limit was also incorporated.
Age, history of angina pectoris, large ST-segment elevation on
the baseline ECG and peak CK .12 were selected as inde-
pendent predictors of mortality. Right ventricular involvement
was not an independent determinant of 30-day cardiac mor-
tality.
Angiographic data. In 187 patients coronary angiography
was performed 90 min after the start of thrombolytic therapy.
The infarct artery was the right coronary artery in 139 patients,
and in 48 patients (26%) it was the circumflex coronary artery.
Right ventricular involvement was present in 69 patients
(37%); in only 2 patients (3%) the circumflex coronary artery
was the infarct vessel. The angiographic data of the 139
patients, in whom the right coronary artery was the infarct
vessel, are presented in Table 5. Right ventricular involvement
Table 1. Clinical Characteristics of 522 Patients With Inferior AMI According to Presence or Absence
of ST-Segment Elevation of $0.1 mV in Lead V4R
ST-Segment Elevation V4R $0.1 mV
Present (n 5 169) Absent (n 5 353) p Value
Mean Age (yr) 60.1 60.5 NS
Female 28.4% 19.3% 0.02
History
Previous MI 12.4% 12.7% NS
Diabetes 10.7% 13.0% NS
Angina pectoris 46.7% 45.0% NS
Current smoker 49.7% 44.5% NS
In-hospital
¥ ST-segment elevation (mV)* 1.05 6 0.67 0.81 6 0.45 ,0.0001
¥ ST-segment deviation (mV)* 1.82 6 0.93 1.64 6 0.84 0.08
No. ST $0.1 mV* 3.44 6 0.92 3.44 6 0.97 NS
Peak CK† 12.1 6 8.9 (5.7, 16.5) 10.5 6 8.3 (4.8, 13.5) 0.03
Large ST
¥ ST elevation (mV)* 1.21 6 0.69 0.94 6 0.47 0.0002
No. ST $0.1 mV* 3.60 6 0.92 3.64 6 0.98 NS
Peak CK† 13.2 6 9.4 (6.2, 17.6) 11.9 6 8.6 (6.3, 15.2) NS
*Mean value 6 SD; †mean fraction of the upper normal limit 6 SD with the median 25th and 75th percentiles shown
in parentheses. AMI 5 acute myocardial infarction; CK 5 creatine kinase isoenzyme serum activity; Large ST 5 presence
of precordial ST-segment depression or sum of ST-segment elevation .0.8 mV on the prerandomization ECG; MI 5
myocardial infarction; No. ST $0.1 mV 5 number of leads with $0.1 mV ST-segment elevation on the prerandomization
ECG; ¥ ST-segment elevation 5 sum of ST-segment elevation on the prerandomization ECG; ¥ ST-segment deviation 5
sum of ST-segment elevation and precordial ST-segment depression on the prerandomization ECG.
Table 2. Clinical Event Rate According to Presence or Absence of
ST-Segment Elevation of $0.1 mV in Lead V4R
ST-Segment Elevation V4R $0.1 mV
Present
(n 5 169)
Absent
(n 5 353)
p
Value
Systolic blood pressure
,100 mm Hg*
5.3% 4.0% NS
Pulse rate ,60/min* 21.3% 19.0% NS
Killip class .1* 11.2% 7.9% NS
Recurrent MI 9.5% 5.1% 0.06
AP/ischemia 15.9% 16.7% NS
Cardiogenic shock 4.7% 2.5% NS
VF/VT 18.9% 12.2% 0.04
Any of above 56.8% 45.9% 0.02
*Present on admission. AP 5 angina pectoris; VF 5 ventricular fibrillation;
VT 5 sustained ventricular tachycardia; other abbreviations as in Table 1.
Table 3. Thirty-Day Mortality According to Presence or Absence of
ST-Segment Elevation of $0.1 mV in Lead V4R
ST-Segment Elevation V4R $0.1 mV
Present (n 5 169) Absent (n 5 353) p Value
Total mortality 7.1% (12/169) 4.1% (15/353) NS
Small ST 2.6% (1/39) 3.7% (4/108) NS
Large ST 8.5% (11/130) 4.5% (11/245) NS
Cardiac mortality 5.9% (10/169) 2.5% (9/353) 0.05
Small ST 0 (0/39) 0.9% (1/108) NS
Large ST 7.7% (10/130) 3.3% (8/245) 0.06
Numbers in parentheses are number of patients. Small ST 5 sum of
ST-segment elevation #0.8 mV and absence of precordial ST-segment depres-
sion on the prerandomization ECG; other abbreviations as in Table 1.
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was present in 67 patients (48%). The coronary lesion was
located proximally to the origin of any right ventricular
branches in 48% with presence, and in 26% with absence of
RVI. The right coronary artery was the dominant vessel more
often in patients without RVI while multivessel disease was
present in about two thirds of all patients. The 90-min post-
thrombolytic therapy patency rate was slightly lower in patients
with RVI. This disparity, however, was entirely caused by an
occluded vessel (mostly located distally) in 11 of 15 patients
with RVI who had small ST on the baseline ECG. With large
ST the patency rates were not different.
Discussion
Right ventricular involvement as assessed by various diag-
nostic criteria has been shown to occur in 30% to 50% of
patients suffering an inferior AMI (6,8,9,17,21). A most accu-
rate and readily available electrocardiographic sign of RVI is
ST-segment elevation of $0.1 mV in the right precordial chest
lead V4R (6,8,16,17). In our study, which is the largest
prospective study on RVI, 32% of all inferior AMI patients
had 0.1 mV or more ST-segment elevation in lead V4R. There
are conflicting data concerning pathologic anatomy, clinical
significance and prognostic implication of RVI in inferior
AMI. Most studies suffer from small sample sizes in selected
groups of patients.
Pathologic anatomy. The infarct vessel in patients suffering
inferior AMI complicated by RVI is the right coronary artery.
Right ventricular involvement only occasionally develops after
occlusion of the circumflex artery, as in our angiographic
substudy in 2 of 48 patients. It is generally believed that it is a
proximal occlusion of the right coronary artery that results in
infarction of the anterolateral wall of the right ventricle, which
is mainly perfused by right ventricular branches (6,11,12,21).
However, pathologic analyses consistently have shown that it is
the posterior right ventricular wall that is most frequently
involved in right ventricular infarction in association with left
ventricular posterior and posteroseptal infarction (6,17,22,23).
Acute vessel lesions were distributed throughout the right
coronary artery tree with a somewhat higher incidence of
proximal location (22,23). Proximal right coronary artery oc-
clusion caused larger right ventricular infarction than distal
occlusion (23). There was no difference between the two
groups in severity of coronary arterial atherosclerosis (22). Our
angiographic data (Table 5) are in concordance with these
pathologic findings. The incidence of multivessel disease was
similar in both groups. Although patients with RVI more often
had a proximal coronary artery lesion than patients without
RVI, in 52% of patients the coronary artery lesion was located
distally of the origin of the right ventricular branch. Of all
patients with proximal lesions, 63% developed RVI. Patients
with a small infarction as assessed by small ST mostly had a
distally located infarct-related coronary artery lesion. In pa-
tients who had large ST-segment elevations, the 90-min post-
thrombolytic therapy patency rate was similar in those with or
without RVI, while patients with small ST and RVI mostly had
an occluded and without RVI mostly had a patent infarct
vessel (Table 5).
Clinical significance of RVI. In most patients with inferior
AMI RVI is not recognized clinically. About one half of
patients with RVI have no clinical abnormalities (6,21). Seri-
ous adverse events that occur are particularly high degree
atrioventricular block, severe bradycardia and malignant ven-
tricular tachyarrhythmias (3,6–9,21). In some studies a high
incidence of cardiogenic shock is reported (7–9). In our study
the incidence of cardiac adverse events in patients with RVI
(Table 2) is similar to that observed in patients with inferior
AMI presenting with large ST (5).
Right ventricular dysfunction in the setting of inferior AMI
is predominantly due to ischemia and probably stunned myo-
cardium (6,21). Right ventricular wall motion abnormalities
and right ventricular ejection fraction substantially improve in
the majority of patients over a few days to several weeks
(10 –13,17,23–26). Pharmacologic reperfusion therapy
(10,12,15,26) or angioplasty (14) may or may not (11,13)
enhance spontaneous recovery of right ventricular dysfunction.
ST-segment elevation in right chest leads indicates right ven-
tricular ischemia rather than necrosis. The relative infrequency
of subsequent right ventricular infarction is believed to be due
Table 4. Multivariate Analysis for Prediction of 30-Day Cardiac
Mortality on the Basis of Presence of RVI $0.1 mV and 9 Other
Variables (A) and After Offering Peak CK .12 Fraction of the
Upper Normal Limit as Additional Variable (B)
Variable
Selected
at Step
OR
(95% CI) p Value
A Age (10-yr steps) 1 2.4 (1.5–3.7) 0.0003
History of angina 2 3.0 (1.1–8.3) 0.04
Large ST 3 6.8 (0.9–51) 0.06
B Age (10-yr steps) 1 2.5 (1.6–4.0) 0.0001
Peak CK .12 2 2.8 (1.1–7.0) 0.02
History of angina 3 3.0 (1.1–8.3) 0.04
CI 5 confidence interval; OR 5 odds ratio.
Table 5. Angiographic Right Coronary Artery Data According to
Presence or Absence of ST-Segment Elevation of $0.1 mV in
Lead V4R
ST-Segment Elevation V4R $0.1 mV
Present (n 5 67) Absent (n 5 72) p Value
Proximal lesion 48% 26% 0.02
Dominant RCA 32% 46% 0.15
$2 Vessel disease 68% 65% NS
Patent IRA 48% 60% NS
Large ST n 5 52 n 5 52
Proximal lesion 52% 23% 0.004
Patent IRA 54% 52% NS
Small ST n 5 15 n 5 20
Proximal lesion 33% 35% NS
Patent IRA 27% 80% 0.004
IRA 5 infarct-related coronary artery; RCA 5 right coronary artery; other
abbreviations as in Tables 1 and 3.
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to a more favorable oxygen supply–demand relation of the
right ventricle as compared to the left ventricle (6,21).
Prognosis related to infarct size. Some (8,9) but not all
(13,24) studies reported that RVI in patients with inferior AMI
is associated with a substantially increased mortality risk. Only
scant data exist from small studies about the impact of
reperfusion therapy on survival in patients with RVI during
inferior AMI (3,10 –15). Unfortunately, the influence of
thrombolytic therapy was not examined in the placebo-
controlled thrombolytic trials. In our study all patients had
thrombolytic therapy. In univariate analysis patients with RVI
had a significantly higher cardiac mortality than patients
without. However, multivariate analysis made it likely that this
increased mortality is due to larger infarct sizes rather than
directly related to the presence of ST-segment elevation in
right chest leads (Table 4). Likewise, as in our study, patients
with RVI had larger maximum cardiac enzyme levels (7–9,27)
and greater impairment of left ventricular function (26). We
recognized, in addition, a larger epicardial injury as quantified
by the sum of ST segment elevation on the baseline ECG in
patients with RVI (Table 1). Several studies have shown that
long-term prognosis was not adversely affected by RVI
(7,13,24–27) but was related to concomitant significant left
ventricular dysfunction (7,25). It is suggested that the higher
mortality in patients with anterior as opposed to inferior AMI,
despite adjustment for infarct size, may in part be due to
coexistent RVI in patients with inferior AMI, resulting in less
left ventricular impairment relative to the total cardiac enzyme
release (7,28).
Clinical implications. There is accumulating evidence that
patients with small inferior AMI do not benefit from throm-
bolysis (4,5,21). Since mortality from cardiac causes is low, the
risks inherent to thrombolytic treatment may lead to an
adverse outcome. Patients in whom thrombolytic therapy may
be contraproductive are those presenting with small ST, that is
sum ST-segment elevation from leads II, III, aVF and V5, V6
#0.8 mV, and no precordial ST-segment depression (5). In
contrast to patients presenting with large ST, left ventricular
function is relatively well preserved also without thrombolysis,
and improvement by thrombolytic therapy is small (5). It is
believed that patients who had inferior AMI complicated by
RVI may particularly benefit from thrombolytic therapy
(3,6,14,15,21,26). Our study shows that patients with inferior
AMI and small ST on admission have a very low cardiac
mortality regardless of whether ST-segment elevation in lead
V4R was present. Of 147 patients with small ST, only 1 suffered
cardiac death, but 4 others died from noncardiac causes. In a
placebo-controlled trial total mortality tended to be higher in
patients with inferior AMI presenting with small ST who had
been allocated to streptokinase therapy (5). Thus, it appears
unlikely that patients with small ST and RVI will benefit from
thrombolysis, the more so as reperfusion was mostly not
achieved 90 min after the start of streptokinase infusion (Table
5). In the usual clinical setting in AMI patients, right ventric-
ular chest leads are often not recorded. Our data suggest that
for early clinical decision making to thrombolytic therapy a
12-lead ECG recording indeed is sufficient. In most cases
patients who have small ST can easily be identified visually
without exact measurements of ST-segment deviation. On the
principle of doing no harm unless one can be reasonably sure
of doing more good than harm (29), reperfusion therapy in
inferior AMI patients presenting with small ST appears not to
be indicated irrespective of presence of RVI unless advanced
heart block or hemodynamic instability indicates larger infarcts
(5,21).
Study limitations. Although this was a prospective study,
only patients eligible for thrombolytic therapy are included and
all patients had thrombolytic therapy within 6 h from symptom
onset. In inferior AMI patients who have large ST-segment
deviation without thrombolytic therapy, the presence of RVI
may be associated with a relatively more unfavorable outcome.
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